Hana Biosciences Appoints Robert Spiegel, M.D., FACP, to Board of Directors
August 05, 2010 08:30 ET
|
Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 5, 2010 (GLOBE NEWSWIRE) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced the...
Hana Biosciences Patent Issued for Menadione for the Prevention and Treatment of EGFR Inhibitor Cancer Therapy-Associated Rash
July 08, 2010 08:30 ET
|
Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 8, 2010 (GLOBE NEWSWIRE) -- Hana Biosciences, Inc. (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced...
Hana Biosciences Announces Financing of Up to $100 Million
June 07, 2010 10:09 ET
|
Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 7, 2010 (GLOBE NEWSWIRE) -- Hana Biosciences Inc., (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced...
Data From Pivotal Phase 2 RALLY Trial Show Marqibo Produced Compelling Single-Agent Anti-Leukemic Efficacy in Advanced Relapsed/Refractory Adult Ph(-) Acute Lymphoblastic Leukemia
June 07, 2010 07:00 ET
|
Talon Therapeutics, Inc.
Marqibo administered as third-, fourth-, fifth-, and sixth-line single-agent therapy
35% overall response rate with a predictable and manageable toxicity profile
20% complete response...
Hana Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference
June 03, 2010 08:30 ET
|
Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 3, 2010 (GLOBE NEWSWIRE) -- Hana Biosciences, Inc. (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced...
Hana Biosciences Reports First Quarter 2010 Financial Results
May 14, 2010 08:30 ET
|
Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 14, 2010 (GLOBE NEWSWIRE) -- Hana Biosciences Inc., (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported...
Hana Biosciences Completes Pre-NDA Meeting With FDA for Marqibo in Adult Acute Lymphoblastic Leukemia
April 27, 2010 08:30 ET
|
Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 27, 2010 (GLOBE NEWSWIRE) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that...
Hana Biosciences to Present Complete Data From Pivotal Phase 2 Trial of Marqibo in Acute Lymphoblastic Leukemia at American Society of Clinical Oncology 2010 Annual Meeting
April 22, 2010 08:30 ET
|
Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 22, 2010 (GLOBE NEWSWIRE) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that...
Hana Biosciences Receives Notice of Allowance for Menadione Patent for the Prevention and Treatment of EGFR Inhibitor Cancer Therapy-Associated Rash
March 30, 2010 08:30 ET
|
Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 30, 2010 (GLOBE NEWSWIRE) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that...
Hana Biosciences Reports Fourth Quarter and Year End 2009 Financial Results
March 25, 2010 16:45 ET
|
Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 25, 2010 (GLOBE NEWSWIRE) -- Hana Biosciences Inc., (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported...